Superior overall survival for tislelizumab plus chemotherapy versus chemotherapy in first-line treatment settingBASEL, Switzerland & BEIJING & CAMBRIDGE, Mass. (BUSINESS WIRE) BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced the global RATIONALE 305 trial met its pr.
Oral presentation for RATIONALE 305 showed improved survival and manageable safety profile for tislelizumab and chemotherapy in gastric or gastroesophageal junction cancer with PD-L1 expression BeiGene
10.09.2022 - BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, shared updates from its solid . Seite 1
Tislelizumab demonstrated non-inferiority for overall survival and favorable safety profile versus sorafenib in global Phase 3 trialAdditional poster presentations show breadth of tislelizumab global clinical development program as single-agent treatment and in combinationCAMBRIDGE, Mass. & BASEL, Switzerland & BEIJ.